Aziridinyldinitrobenzamides: Synthesis and structure-activity relationships for activation by E. coli nitroreductase

Journal of Medicinal Chemistry

Volumn 47, Issue 12, 2004, Pages 3295-3307

  Helsby, Nuala A ^a   Atwell, Graham J ^a   Yang, Shangjin ^a   Palmer, Brian D ^a   Anderson, Robert F ^a   Pullen, Susan M ^a   Ferry, Dianne M ^a   Hogg, Alison ^a   Wilson, William R ^a   Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

2 AZIRIDINYL 3,5 DINITROBENZAMIDE; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 5 (AZIRIDIN 1 YL) N (2,3 DIHYDROXYPROPYL) 2,4 DINITROBENZAMIDE; ACID; AMIDE; AZIRIDINE DERIVATIVE; AZIRIDINYLDINITROBENZAMIDE; BENZAMIDE DERIVATIVE; HYDROXYLAMINE; NITROBENZENE DERIVATIVE; NITROREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; BYSTANDER EFFECT; CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CELL LINE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG SPECIFICITY; DRUG STRUCTURE; GENE DIRECTED ENZYME PRODRUG THERAPY; ISOMER; MOUSE; NONHUMAN; NUDE MOUSE; PULSE RADIOLYSIS; REDUCTION; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; BENZAMIDES; CELL LINE, TUMOR; CRICETINAE; DRUG SCREENING ASSAYS, ANTITUMOR; ESCHERICHIA COLI PROTEINS; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASM TRANSPLANTATION; NITROREDUCTASES; OXIDATION-REDUCTION; PRODRUGS; SOLUBILITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 2542574086     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0498699     Document Type: Article

References (55)

1. Greco, O.; Dachs, G. U. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J. Cell. Physiol. 2001, 187, 22-36.
2. Michael, N. P.; Brehm, J. K.; Anlezark, G. M.; Minton, N. P. Physical characterisation of the Escherichia coli B gene encoding nitroreductase and its over-expression in Escherichia coli K12. FEMS Microbiol. Lett. 1994, 124, 195-202.
3. Zenno, S.; Koike, H.; Tanokura, M.; Saigo, K. Gene cloning, purification, and characterization of NfsB, a minor oxygen-insensitive nitroreductase from Escherichia coli, similar in biochemical properties to FRase I, the major flavin reductase in Vibrio fischeri. J. Biochem. (Tokyo) 1996, 120, 736-744.
4. Anlezark, G. M.; Melton, R. G.; Sherwood, R. F.; Coles, B.; Friedlos, F. ; Knox, R. J. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954). I. Purification and properties of a nitroreductase enzyme from Escherichia coli-a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol. 1992, 44, 2289-2295.
5. Lovering, A. L.; Hyde, E. I.; Searle, P. F.; White, S. A. The structure of Escherichia coli nitroreductase complexed with nicotinic acid: three crystal forms at 1.7, 1.8, and 2.4 Å resolution. J. Mol. Biol. 2001, 309, 203-213.
6. Parkinson, G. N.; Skelly, J. V.; Neidle, S. Crystal structure of FMN-dependent nitroreductase from Escherichia coli B: a prodrug-activating enzyme. J Med. Chem. 2000, 43, 3624-3631.
7. Knox, R. J.; Boland, M. P.; Friedlos, F.; Coles, B.; Southan, C.; Roberts, J. J. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem. Pharmacol. 1988, 37, 4671-4677.
8. Boland, M. P.; Knox, R. J.; Roberts, J. J. The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). Biochem. Pharmacol. 1991, 41, 867-875.
9. Knox, R. J.; Jenkins, T. C.; Hobbs, S. M.; Chen, S.; Melton, R. G.; Burke, P. J. Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy. Cancer Res. 2000, 60, 4179-4186.
10. Bridgewater, J. A.; Springer, C. J.; Knox, R. J.; Minton, N. P.; Michael, N. P.; Collins, M. K. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer 1995, 31A, 2362-2370.
11. McNeish, I. A.; Green, N. K.; Gilligan, M. G.; Ford, M. J.; Mautner, V.; Young, L. S.; Kerr, D. J.; Searle, P. F. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Ther. 1998, 5, 1061-1069.
12. Green, N. K.; Youngs, D. J.; Neoptolemos, J. P.; Friedlos, F.; Knox, R. J.; Springer, C. J.; Anlezark, G. M.; Michael, N. P.; Melton, R. G.; Ford, M. J.; Young, L. S.; Kerr, D. J.; Searle, P. F. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther. 1997, 4, 229-238.
13. Friedlos, F.; Court, S.; Ford, M.; Denny, W. A.; Springer, C. Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase. Gene Ther. 1998, 5, 105-112.
14. Djeha, A. H.; Hulme, A.; Dexter, M. T.; Mountain, A.; Young, L. S.; Searle, P. F.; Kerr, D. J.; Wrighton, C. J. Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954. Cancer Gene Ther. 2000, 7, 721-731.
15. Wilson, W. R.; Pullen, S. M.; Hogg, A.; Helsby, N. A.; Hicks, K. O.; Denny, W. A. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Res. 2002, 62, 1425-1432.
16. Chung-Faye, G.; Palmer, D.; Anderson, D.; Clark, J.; Downes, M.; Baddeley, J.; Hussain, S.; Murray, P. I.; Searle, P.; Seymour, L.; Harris, P. A.; Ferry, D.; Kerr, D. J. Virus-Directed, Enzyme Prodrug Therapy with Nitroimidazole Reductase: A Phase I and Pharmacokinetic Study of Its Prodrug, CB1954. Clin. Cancer Res. 2001, 7, 2662-2668.
17. Clark, A. J.; Iwobi, M.; Cui, W.; Crompton, M.; Harold, G.; Hobbs, S.; Kamalati, T.; Knox, R.; Neil, C.; Yull, F.; Gusterson, B. Selective cell ablation in transgenic mice expression E. coli nitroreductase. Gene Ther. 1997, 4, 101-110.
18. Cui, W.; Allen, N. D.; Skynner, M.; Gusterson, B.; Clark, A. J. Inducible ablation of astrocytes shows that these cells are required for neuronal survival in the adult brain. Glia 2001, 34, 272-282.
19. Cui, W.; Gusterson, B.; Clark, A. J. Nitroreductase-mediated cell ablation is very rapid and mediated by a p53-independent apoptotic pathway. Gene Ther. 1999, 6, 764-770.
20. Cui, W.; Gusterson, B. A.; Clark, A. J. Inhibition of myc-dependent breast tumor formation in transgenic mice. Breast Cancer Res. Treat. 2002, 71, 9-20.
21. Gusterson, B.; Cui, W.; Iwobi, M.; Crompton, M. R.; Harold, G.; Hobbs, S.; Kamalati, T.; Knox, R.; Neil, C.; Yull, F.; Howard, B.; Clark, A. J. Selective cell ablation in the mammary gland of transgenic mice. Endocr.-Relat. Cancer 1997, 4, 67-74.
22. Isles, A. R.; Ma, D.; Milsom, C.; Skynner, M.; Cui, W.; Clark, J.; Keverne, E. B.; Allen, N. D. Conditional ablation of neurones in transgenic mice. J. Neurobiol. 2001, 47, 183-193.
23. Felmer, R.; Cui, W.; Clark, A. J. Inducible ablation of adipocytes in adult transgenic mice expressing the E. coli nitroreductase gene. J. Endocrinol. 2002, 175, 487-498.
24. Ma, D.; Allen, N. D.; Van Bergen, Y. C.; Jones, C. M.; Baum, M. J.; Keverne, E. B.; Brennan, P. A. Selective ablation of olfactory receptor neurons without functional impairment of vomeronasal receptor neurons in OMP-ntr transgenic mice. Eur. J. Neurosci. 2002, 16, 2317-2323.
25. Knox, R. J.; Friedlos, F.; Sherwood, R. F.; Melton, R. G.; Anlezark, G. M. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954). II. A comparison of an Eschericia coli nitroreductase and Walker DT diaphorase. Biochem. Pharmacol. 1992, 44, 2297-2301.
26. Johansson, E.; Parkinson, G.; Denny, W. A.; Neidle, S. Studies on the Nitroreductase Prodrug System. Crystal Structures of Complexes with the Inhibitor Dicoumarol and Dinitrobenzamide Prodrugs and of the Enzyme Active Form. J. Med. Chem. 2003, 46, 4009-4020.
27. Bridgewater, J. A.; Knox, R. J.; Pitts, J. D.; Collins, M. K.; Springer, C. J. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Hum. Gene Ther. 1997, 8, 709-717.
28. Knox, R. J.; Friedlos, F.; Jarman, M.; Robert, J. J. A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydrozylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by nitroreductase enzyme in Walker carcinoma cells. Biochem. Pharmacol. 1988, 37, 4661.
29. Knox, R. J.; Friedlos, F.; Marchbank, T.; Roberts, J. J. Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species. Biochem. Pharmacol. 1991, 42, 1691-1697.
30. Helsby, N. A.; Wheeler, S. J.; Pruijn, F. B.; Palmer, B. D.; Yang, S.; Denny, W. A.; Wilson, W. R. Effect of Nitroreduction on the Alkylating Reactivity and Cytotoxicity of the 2,4-Dinitrobenzamide-5-aziridine CB 1954 and the Corresponding Nitrogen Mustard SN 23862: Distinct Mechanisms of Bioreductive Activation. Chem. Res. Toxicol. 2003, 16, 469-478.
31. Helsby, N. A.; Ferry, D. M.; Patterson, A. V.; Pullen, S. M.; Wilson, W. R. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT. Br. J. Cancer 2004, 90, 1084-1092.
32. Goldstein, H.; Stamm, R. On 5-chloro-2,4-dinitrobenzoic acid. Helv. Chim. Acta 1952, 35, 1330-1333.
33. Johnson, W. O. Nitro- and trifluoromethyl-substituted diphenyl ethers. Chem. Abstr. 1981, 94, 15653h.
34. Atwell, G. J.; Boyd, M.; Palmer, B. D.; Anderson, R. F.; Pullen, S. M.; Wilson, W. R.; Denny, W. A. Synthesis and evaluation of 4-substituted analogues of 5-[N,N-bis(2-chloroethyl)amino]-2-nitrobenzamide as bioreductively activated prodrugs using an Escherichia coli nitroreductase. Anti-Cancer Drug Des. 1996, 11, 553-567.
35. Somani, H. H.; Wilman, D. E. Novel analogues of CB 1954: Their potential use in an antibody directed enzyme prodrug therapy (ADEPT) strategy. Br. J. Cancer 1994, 69, 38.
36. Palmer, B. D.; Wilson, W. R.; Anderson, R. F.; Boyd, M.; Denny, W. A. Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. J. Med. Chem. 1996, 39, 2518-2528.
37. Jarman, M.; Melzack, D. H.; Ross, W. C. J. The metabolism of the anti-tumour agent 5-(1-aziridinyl)-2,4-dinitrobenzamide (CB 1954). Biochem. Pharmacol. 1976, 25, 2475-2478.
38. Patel, K. B.; Willson, R. L. Semiquinone free radicals and oxygen. Pulse radiolysis study of one-electron transfer equilibria. J. Chem. Soc., Faraday Trans. 1973, 69, 814-819.
39. Hobbs, S.; Jitrapakdee, S.; Wallace, J. C. Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1alpha promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins. Biochem. Biophys. Res. Commun. 1998, 252, 368-372.
40. 6-alkylguanine alkyltransferase activity in Chinese hamster V79 cells following selection with chloroethylating agents. Carcinogenesis 1988, 9, 45-49.
41. Palmer, B. D.; van Zijl, P.; Denny, W. A.; Wilson, W. R. Reductive chemistry of the novel hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. J. Med. Chem. 1995, 38, 1229-1241.
42. Skelly, J. V.; Knox, R. J.; Jenkins, T. C. Aerobic nitroreduction by flavoproteins: enzyme structure, mechanisms and role in cancer chemotherapy. Mini-Rev. Med. Chem. 2001, 1, 293-306.
43. Ross, D.; Kepa, J. K.; Winski, S. L.; Beall, H. D.; Anwar, A.; Siegel, D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem. Biol. Interact. 2000, 129, 77-97.
44. Belcourt, M. F.; Hodnick, W. F.; Rockwell, S.; Sartorelli, A. C. Bioactivation of mitomycin antibiotics by aerobic and hypoxic Chinese hamster ovary cells overexpressing DT-diaphorase. Biochem. Pharmacol. 1996, 51, 1669-1678.
45. Cobb, L. M. Toxicity of the selective antitumor agent 5-aziridino-2,4-dinitrobenzamide in the rat. Toxicol. Appl. Pharmacol. 1970, 17, 231-238.
46. Friedlos, F.; Denny, W. A.; Palmer, B. D.; Springer, C. J. Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy. J. Med. Chem. 1997, 40, 1270-1275.
47. Schmelkes, F. C.; Rubin, M. Substituted p-aminobenzoic acids. J. Am. Chem. Soc. 1944, 66, 1631-1632.
48. Ruff, F.; Kapovits, I.; Rabai, J.; Kucsman, A. Neighboring group participation in reactions of sulfides with chloramine-T. Tetrahedron 1978, 34, 2767-2773.
49. Protiva, M.; Jilek, J.; Rajsner, M.; Pomykacek, J.; Ryska, M.; Holubek, J.; Svatek, E.; Metysova, J. Fluorinated tricyclic neuroleptics with prolonged action. 7-Fluoro-11-[4-(2-hydroxyethyl)piperazino]-2-isopropyl-10,11-dihydrodibenzo[b,f] thiepin. Collect. Czech. Chem. Commun. 1986, 51, 698-722.
50. Denny, W. A.; Atwell, G. J.; Palmer, B. D.; Wilson, W. R. Nitrophenylaziridine compounds and their uses as prodrugs. U.S. Patent 6,517,836, 2003
51. Hostetler, W.; Reinheimer, J. D. Aromatic nucleophilic substitution. Specific salt effects on rate constants with benzyltrimethyl-ammonium methoxide in methanol. J. Org. Chem. 1968, 33, 3510-3513.
52. Denny, W. A.; Atwell, G. J.; Roberts, P. B.; Anderson, R. F.; Boyd, M.; Lock, C. J.; Wilson, W. R. Hypoxia-seleetive antitumor agents. 6.4-(Alkylamino)nitroquinolines: a new class of hypoxia-selective cytotoxins. J. Med. Chem. 1992, 35, 4832-4841.
53. Wilson, W. R.; Pullen, S. M.; Hogg, A.; Hobbs, S. M.; Pruijn, F. B.; Hicks, K. O. In vitro and in vivo models for evaluation of GDEPT: quantifying bystander killing in cell cultures and tumors. In Suicide Gene Therapy: Methods and Reviews; Springer, C. J., Ed.; Humana Press: Totowa, NJ, 2003; pp 403-432.
54. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112.
55. Pruijn, F. B.; Hogg, A.; Helsby, N. A.; Pullen, S. M.; Hicks, K. O.; Denny, W. A.; Wilson, W. R. SN 26209, a novel orally active NTR-GDEPT prodrug: Pharmacokinetics and in vivo activity against xenografts expressing E. coli nitroreductase. Cancer Chemother. Pharmacol., submitted.